Therapeutic Asset Ratings
212 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Zoladex
Gastric Cancer
Blueprint Medicines Corporation
P1
C
(37)
(3RS)-1-(6-(.ALPHA.-METHYLPOLY(OXYETHYLENE)AMINO)-6-OXOHEXYL)-2,5-DIOXOPYRROLIDIN-3-YL)-L-CYSTEINAMIDE, (20000 MW)
Gastric Cancer
Lumicell, Inc.
P1/2
C
(37)
Fosifloxuridine Nafalbenamide
Gastric Cancer
NuCana plc
P1/2
C
(35)
R130
Gastric Cancer
Shanghai Yunying Medical Technology
Early P1
C
(34)
HUMAN INTERLEUKIN 2 (IL2, T-CELL GROWTH FACTOR, TCGF) (2-133) VARIANT (A1 DELETED, PRO65>LYS, CYS125>SER), NON-GLYCOSYLATED, PRODUCED IN ESCHERICHIA COLI, CONJUGATED AT N6 OF K65 WITH A PEG DERIVATIVE (30KDA)
Gastric Cancer
Sanofi
P2
C
(33)
Milademetan
Gastric Cancer
Rain Oncology Inc
P1/2
D
(30)
Chimeric Antigen Receptor T Cell Preparation Targeting Claudin18.2
Gastric Cancer
The Affiliated Hospital of Qingdao University
N/A
D
(28)
Indocyanine Green
Gastric Cancer
Saint Petersburg State University, Russia
N/A
D
(28)
MEGESTROL ACETATE IMPURITY B
Gastric Cancer
Changchun GeneScience Pharmaceutical Co., Ltd.
D
(28)
Nano-Crystalline Megestrol Acetate Suspension
Gastric Cancer
Changchun GeneScience Pharmaceutical Co., Ltd.
D
(28)
Recombinant Mutant Human Tumor Necrosis Factor
Gastric Cancer
Wuhan University
D
(28)
Sasanlimab
Gastric Cancer
Pfizer
P1
D
(26)
Showing 201 to 212 of 212 assets
Previous
Page 9 of 9
Next
